Growth Metrics

Merck (MRK) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 76.98%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 318.57%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 44.22%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -52.54%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -14.16%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 26.25%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -21.46%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 6.98%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -52.54%
Dec 31, 2025 0.56%
Sep 30, 2025 21.92%
Jun 30, 2025 4.33%
Mar 31, 2025 5.74%
Dec 31, 2024 7.24%
Sep 30, 2024 -11.68%
Jun 30, 2024 51.95%
Mar 31, 2024 20.08%
Dec 31, 2023 16.69%
Sep 30, 2023 17.04%
Jun 30, 2023 -65.76%
Mar 31, 2023 -4.14%
Dec 31, 2022 8.65%
Sep 30, 2022 20.04%
Jun 30, 2022 14.59%
Mar 31, 2022 14.92%
Dec 31, 2021 20.26%
Sep 30, 2021 35.10%
Jun 30, 2021 -1.07%
Mar 31, 2021 58.74%
Dec 31, 2020 -29.75%
Sep 30, 2020 291.49%
Jun 30, 2020 9.02%
Mar 31, 2020 31.04%
Dec 31, 2019 85.48%
Sep 30, 2019 -1.74%
Jun 30, 2019 33.80%
Mar 31, 2019 40.95%
Dec 31, 2018 26.61%
Sep 30, 2018 4.48%
Jun 30, 2018 37.95%
Mar 31, 2018 -6.47%
Dec 31, 2017 -29.11%
Sep 30, 2017 -27.33%
Jun 30, 2017 1.45%
Mar 31, 2017 -0.59%
Dec 31, 2016 -40.57%
Sep 30, 2016 27.09%
Jun 30, 2016 12.75%
Mar 31, 2016 -8.37%
Dec 31, 2015 5.45%
Sep 30, 2015 4.55%
Jun 30, 2015 -25.48%
Mar 31, 2015 -16.16%
Dec 31, 2014 72.15%
Sep 30, 2014 -17.40%
Jun 30, 2014 1.52%
Mar 31, 2014 18.80%
Dec 31, 2013 54.49%
Sep 30, 2013 51.17%
Jun 30, 2013 7.72%
Mar 31, 2013 79.44%
Dec 31, 2012 -51.99%
Sep 30, 2012 -29.67%
Jun 30, 2012 -7.80%
Mar 31, 2012 -5.80%